Clinical Trial Update: Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan [Phase 3]

View source ↗

Summary

Phase 3 trial comparing sacubitril/valsartan (LCZ696) to olmesartan in essential hypertension patients not adequately controlled on olmesartan, assessing effica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Entresto (sacubitril/valsartan) (sacubitril/valsartan)
• Olmesartan (olmesartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2015-12-07